About CG Oncology, Inc. Common stock
https://cgoncology.comCG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer.
CEO
Arthur Kuan
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 133
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
RBC Capital
Outperform
JP Morgan
Overweight
Morgan Stanley
Overweight
Cantor Fitzgerald
Overweight
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:6.58M
Value:$365.1M
DECHENG CAPITAL LLC
Shares:6.37M
Value:$353.69M
WELLINGTON MANAGEMENT GROUP LLP
Shares:5.51M
Value:$306.01M
Summary
Showing Top 3 of 184
About CG Oncology, Inc. Common stock
https://cgoncology.comCG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.67M ▲ | $51.22M ▲ | $-43.81M ▼ | -2.63K% ▼ | $-0.57 ▼ | $-43.39M ▼ |
| Q2-2025 | $0 ▼ | $48.59M ▲ | $-41.43M ▼ | 0% ▲ | $-0.54 ▼ | $-41.27M ▲ |
| Q1-2025 | $52K ▼ | $42.26M ▲ | $-34.45M ▼ | -66.25K% ▼ | $-0.45 ▲ | $-42.18M ▼ |
| Q4-2024 | $456K ▲ | $38.51M ▲ | $-31.8M ▼ | -6.97K% ▲ | $-0.49 ▼ | $-38.05M ▼ |
| Q3-2024 | $43K | $28.34M | $-20.41M | -47.45K% | $-0.3 | $-28.27M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $680.26M ▲ | $729.91M ▲ | $42.27M ▲ | $687.64M ▲ |
| Q2-2025 | $661.05M ▼ | $701.45M ▼ | $31.09M ▲ | $670.36M ▼ |
| Q1-2025 | $688.43M ▼ | $728.18M ▼ | $23.42M ▲ | $704.76M ▼ |
| Q4-2024 | $742M ▲ | $754.8M ▲ | $21.42M ▲ | $733.38M ▲ |
| Q3-2024 | $540.71M | $552.47M | $15.7M | $536.77M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-43.81M ▼ | $-38.89M ▼ | $15.04M ▲ | $54.37M ▲ | $30.52M ▲ | $-38.99M ▼ |
| Q2-2025 | $-41.43M ▼ | $-27.96M ▲ | $1.41M ▲ | $-296K ▼ | $-26.85M ▲ | $-27.97M ▲ |
| Q1-2025 | $-34.45M ▼ | $-29.28M ▼ | $-186.77M ▼ | $450K ▼ | $-215.6M ▼ | $-29.29M ▼ |
| Q4-2024 | $-31.8M ▼ | $-20.66M ▼ | $10.9M ▼ | $223.41M ▲ | $213.66M ▲ | $-20.87M ▼ |
| Q3-2024 | $-20.41M | $-15.92M | $32.01M | $2.17M | $18.25M | $-15.92M |
CEO
Arthur Kuan
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 133
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
RBC Capital
Outperform
JP Morgan
Overweight
Morgan Stanley
Overweight
Cantor Fitzgerald
Overweight
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:6.58M
Value:$365.1M
DECHENG CAPITAL LLC
Shares:6.37M
Value:$353.69M
WELLINGTON MANAGEMENT GROUP LLP
Shares:5.51M
Value:$306.01M
Summary
Showing Top 3 of 184